Bank of America reiterated its Neutral on Boston Scientific BSX as the company prepares for the coming of a new CEO.
In a research report published today, Bank of America states, "We remain on the sidelines with BSX as we continue to assess the implications of
Mr. Elliott's pending departure on BSX's turnaround. 2012 will be a year of
multiple cross currents for BSX with a new CEO on board, new competitive
threats from STJ and MDT in both stents and CRM, BSX's US launch of Promus
Element (late 2011), the revenue benefit from JNJ's stent market exit (year end
2011) and the potential for more aggressive use of the balance sheet."
At the moment, Bank of America has a price target of $8.50 placed on the company's stock. On Tuesday, Boston Scientific added 2.67% to its value to end the day at $6.92.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsBank of Americaboston scientificHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in